Go to JCI Insight
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
  • Clinical Research and Public Health
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Gastroenterology
    • Immunology
    • Metabolism
    • Nephrology
    • Neuroscience
    • Oncology
    • Pulmonology
    • Vascular biology
    • All ...
  • Videos
    • Conversations with Giants in Medicine
    • Video Abstracts
  • Reviews
    • View all reviews ...
    • Clinical innovation and scientific progress in GLP-1 medicine (Nov 2025)
    • Pancreatic Cancer (Jul 2025)
    • Complement Biology and Therapeutics (May 2025)
    • Evolving insights into MASLD and MASH pathogenesis and treatment (Apr 2025)
    • Microbiome in Health and Disease (Feb 2025)
    • Substance Use Disorders (Oct 2024)
    • Clonal Hematopoiesis (Oct 2024)
    • View all review series ...
  • Viewpoint
  • Collections
    • In-Press Preview
    • Clinical Research and Public Health
    • Research Letters
    • Letters to the Editor
    • Editorials
    • Commentaries
    • Editor's notes
    • Reviews
    • Viewpoints
    • 100th anniversary
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • Reviews
  • Review series
  • Conversations with Giants in Medicine
  • Video Abstracts
  • In-Press Preview
  • Clinical Research and Public Health
  • Research Letters
  • Letters to the Editor
  • Editorials
  • Commentaries
  • Editor's notes
  • Reviews
  • Viewpoints
  • 100th anniversary
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Advertising
  • Job board
  • Contact
Portable flanking sequences modulate CTL epitope processing
Sylvie Le Gall, Pamela Stamegna, Bruce D. Walker
Sylvie Le Gall, Pamela Stamegna, Bruce D. Walker
View: Text | PDF
Technical Advance

Portable flanking sequences modulate CTL epitope processing

  • Text
  • PDF
Abstract

Peptide presentation is critical for immune recognition of pathogen-infected cells by CD8+ T lymphocytes. Although a limited number of immunodominant peptide epitopes are consistently observed in diseases such as HIV-1 infection, the relationship between immunodominance and antigen processing in humans is largely unknown. Here, we have demonstrated that endogenous processing and presentation of a human immunodominant HIV-1 epitope is more efficient than that of a subdominant epitope. Furthermore, we have shown that the regions flanking the immunodominant epitope constitute a portable motif that increases the production and antigenicity of otherwise subdominant epitopes. We used a novel in vitro degradation assay involving cytosolic extracts as well as endogenous intracellular processing assays to examine 2 well-characterized HIV-1 Gag overlapping epitopes presented by the same HLA class I allele, one of which is consistently immunodominant and the other subdominant in infected persons. The kinetics and products of degradation of HIV-1 Gag favored the production of peptides encompassing the immunodominant epitope and destruction of the subdominant one. Notably, cytosolic digestion experiments revealed flanking residues proximal to the immunodominant epitope that increased the production and antigenicity of otherwise subdominant epitopes. Furthermore, specific point mutations in these portable flanking sequences modulated the production and antigenicity of epitopes. Such portable epitope processing determinants provide what we believe is a novel approach to optimizing CTL responses elicited by vaccine vectors.

Authors

Sylvie Le Gall, Pamela Stamegna, Bruce D. Walker

×

Figure 2

The cytosolic processing of Gag fragments facilitates the generation of an immunodominant epitope and the progressive loss of the subdominant one.

Options: View larger image (or click on image) Download as PowerPoint
The cytosolic processing of Gag fragments facilitates the generation of ...
8 nmol of a Gag 17-mer (A) or 32-mer (C) were incubated with 40 μg PBMC cytosol for increasing periods of time. Peptides encompassing both epitopes (black bars), RK9 only (blue bars), KK9 only (green bars), or no epitope (white bars) were identified by mass spectrometry. Optimal RK9 and KK9 are indicated with blue and green stars. Another HLA-A3 epitope, RY10 (RLRPGGKKKY), codominant with RK9 in acute infection (19), was detected (white star). (B) Digestion products were fractioned on a C18 column and identified and quantified by RP-HPLC. Each peptide is identified by a unique peak at a defined elution time and quantified by the surface under peak. The column was calibrated with defined amounts of peptides covering the corresponding HIV sequence. The identity of the peptides in the digestion mix was confirmed by mass spectrometry. Peptides containing RK9 and KK9 epitopes (RK9+/KK9+, circles), RK9 only (RK9+/KK9–, squares), or KK9 only (RK9–/KK9+, triangles) were quantified over a 3-hour digestion with PBMC cytosol. Data are the average of 3 experiments performed with extracts from 3 healthy donors. The kinetics of peptide production using both the 17-mer and the 32-mer was affected by the amount of cytosol used for the experiment, with high amounts of cytosol yielding a more rapid appearance of RK9 and KK9 (not shown).

Copyright © 2026 American Society for Clinical Investigation
ISSN: 0021-9738 (print), 1558-8238 (online)

Sign up for email alerts